Several studies have demonstrated that Recombinant human soluble thrombomodulin (rhTM) has potential advantages for the treatment for patients with infection complicated by disseminated intravascular coagulation (DIC).However, whether injection of rhTMcan affect themortality of those patients in clinical treatment remains controversial.Therefore, we conducted ameta-analysis to evaluate the clinical efficacy for patientswith infection complicated by DIC.
